Developer docs
API playgroundTry for free, no card

Search company profiles

Spyre Therapeutics

Full company profile

uuid00007tu

Namestring
Spyre Therapeutics
Legal namestring
Spyre Therapeutics, Inc.
Websiteurl
spyre.com
Company typeenum
Public
Founded yearint
2023
Descriptiontext

Spyre Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel half-life extended monoclonal antibodies for inflammatory bowel disease (IBD) and rheumatic diseases. The company was rebranded in late 2023 from Aeglea BioTherapeutics and is publicly traded on NASDAQ under the ticker SYRE, headquartered in Waltham, Massachusetts, with 101–250 employees. Its core scientific platform applies the YTE modification to FcRn-binding regions of antibodies, producing a greater than 3x half-life extension that enables quarterly or twice-annual subcutaneous dosing compared with bi-weekly dosing for approved standards of care such as Takeda's Entyvio.

The pipeline comprises three monotherapy candidates (SPY001 targeting α4β7, SPY002 targeting TL1A, and SPY003 targeting IL-23) plus three fixed-dose combination products (SPY120, SPY130, SPY230) coformulated in single injectors, and a distinct anti-TL1A antibody (SPY072) for rheumatic indications. All candidates are investigational and being evaluated in Phase 2 studies including the SKYLINE-UC and SKYWAY-RD trials. Phase 2 data for SPY001 showed 40% clinical remission at Week 12 versus 27% for Entyvio, with 51% endoscopic improvement versus 41%, while SPY003 demonstrated approximately an 85-day confirmed half-life in interim Phase 1 results.

The business model is pre-revenue biopharmaceutical product sales contingent on regulatory approval; no products are approved or commercialized, and there are no published prices. The company has no commercial distribution infrastructure, but has appointed a Chief Commercial Officer (Kate Tansey Chevlen) in January 2026 to prepare for potential commercialization. As of year-end 2025, Spyre held approximately $757 million in cash, cash equivalents, and marketable securities, expected to fund operations into the second half of 2028, supported by capital raises totaling approximately $866.5 million across April 2026 offerings, $316.2 million in October 2025, and a $180 million private placement in March 2024.

Short descriptiontext

Spyre Therapeutics is a clinical-stage biotechnology company developing YTE-modified monoclonal antibodies (SPY001, SPY002, SPY003, SPY072) and fixed-dose combinations for inflammatory bowel disease and rheumatic diseases, targeting quarterly or twice-annual dosing versus bi-weekly standards of care.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersWaltham, United States
HQ citystring
Waltham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
inflammatory bowel disease therapeutics, monoclonal antibody development, clinical-stage biotechnology, immunology pipeline drugs, rheumatic disease biologics
Industry2 codes
PRIMARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Clinical-Stage Biopharmaceuticals (Immunology / IBD / Rheumatic Disease)
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Biopharmaceutical Product Sales
TypeOne Time License
Description

Pre-revenue clinical-stage biotechnology company. The company is developing a pipeline of novel antibody therapeutics targeting inflammatory bowel disease and rheumatic diseases. Upon successful clinical development and regulatory approval, the company plans to commercialize its pipeline candidates. No products have been approved or commercialized yet.

spyre.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Spyre Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel, half-life extended monoclonal antibodies targeting validated mechanisms (α4β7, TL1A, IL-23) for the treatment of inflammatory bowel disease (ulcerative colitis, Crohn's disease) and rheumatic diseases (rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis). The pipeline includes monotherapy candidates (SPY001, SPY002, SPY003, SPY072) and fixed-dose combination products (SPY120, SPY130, SPY230), all incorporating the YTE modification technology for extended half-life enabling quarterly or twice annual subcutaneous dosing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • SPY001 achieved 40% clinical remission rate at Week 12 vs 27% for Entyvio in ulcerative colitis
+4 more records
Product overview1 text field

Spyre Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel half-life extended monoclonal antibodies targeting validated mechanisms for gastrointestinal and rheumatic diseases. The company's portfolio includes monotherapy candidates (SPY001 targeting α4β7, SPY002 targeting TL1A, SPY003 targeting IL-23) and combination products (SPY120, SPY130, SPY230) that pair these antibodies for enhanced efficacy. All antibodies incorporate the YTE modification for extended half-life enabling quarterly or twice annual dosing. The company is also developing SPY072, a distinct anti-TL1A antibody for rheumatic diseases.

Product and service7 records
1SPY001
CategoryClinical-stage monoclonal antibody candidate
Description

Novel, half-life extended monoclonal antibody targeting α4β7 for the potential treatment of inflammatory bowel disease (IBD), with demonstrated similar potency and selectivity as vedolizumab in preclinical studies and a differentiated pharmacokinetic profile supporting quarterly or twice annual maintenance dosing. Currently in Phase 2 clinical development (SKYLINE-UC).

2SPY002
CategoryClinical-stage monoclonal antibody candidate
Description

Novel, half-life extended monoclonal antibody targeting TL1A for the potential treatment of inflammatory bowel disease, exhibiting comparable or superior potency to first-generation anti-TL1As in head-to-head preclinical studies. Currently in Phase 2 clinical development (SKYLINE-UC trial; achieved 33% clinical remission and 42% endoscopic improvement at Week 12).

3SPY003
CategoryClinical-stage monoclonal antibody candidate
Description

Novel, half-life extended monoclonal antibody targeting IL-23 for the potential treatment of inflammatory bowel disease, exhibiting comparable potency to risankizumab in head-to-head preclinical studies and an approximately 85-day confirmed half-life in interim Phase 1 results. Currently in Phase 2 clinical development.

4SPY120
CategoryClinical-stage fixed-dose combination product
Description

High-concentration fixed-dose combination of SPY001 (anti-α4β7) and SPY002 (anti-TL1A) for the potential treatment of IBD, with superior efficacy compared to either monotherapy alone in preclinical colitis models, coformulated for delivery in a single injector on a quarterly or twice annual basis.

5SPY130
CategoryClinical-stage fixed-dose combination product
Description

High-concentration fixed-dose combination of SPY001 (anti-α4β7) and SPY003 (anti-IL-23) for the potential treatment of IBD, demonstrating additive efficacy in preclinical colitis models, coformulated for single-injector delivery on a quarterly or twice annual basis.

6SPY230
CategoryClinical-stage fixed-dose combination product
Description

High-concentration fixed-dose combination of SPY002 (anti-TL1A) and SPY003 (anti-IL-23) for the potential treatment of IBD, demonstrating additive efficacy in preclinical models, coformulated for single-injector delivery on a quarterly or twice annual basis.

7SPY072
CategoryClinical-stage monoclonal antibody candidate
Description

Novel, half-life extended monoclonal antibody targeting TL1A for the potential treatment of rheumatic diseases including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). Distinct from SPY002 which is being studied in IBD. Currently in Phase 2 clinical development (SKYWAY-RD).

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Markets Skyrizi (risankizumab, anti-IL-23) and Humira in IBD/rheumatic diseases. Directly competes with SPY003 in IL-23 mechanism and sets the efficacy bar Spyre's programs must clear.

TypeBroad incumbent
Description

Markets Tremfya (anti-IL-23) and Stelara in IBD and rheumatic indications. Major incumbent across Spyre's two therapeutic areas with established commercial infrastructure.

TypeBroad incumbent
Description

Markets mirikizumab (Omvoh) in ulcerative colitis and acquired Morphic for its integrin pipeline. Direct competitor in IBD and a likely strategic acquirer of immunology-focused biotechs.

TypeDirect peer
Description

Clinical-stage immunology biotech developing antibody therapies for inflammatory diseases, with overlapping TL1A and IL-23 programs in IBD. Board member Michael Henderson is CEO of Apogee, creating direct portfolio overlap with Spyre.

5Prometheus Biosciences
TypeDirect peer
Description

Was a clinical-stage IBD-focused biotech developing TL1A antibody therapy (PRA023) before being acquired by Merck for $10.8B. Directly comparable pipeline focus and the source of multiple Spyre team members.

6Morphic Holding
TypeDirect peer
Description

Clinical-stage biotech developing oral integrin therapies for IBD, acquired by Eli Lilly for ~$3.2B. Directly comparable as an IBD-focused immunology platform targeting validated mechanisms with differentiated delivery.

TypeEmerging player
Description

Recently formed immunology biotech led by Mark McKenna (Spyre board member). Pursues precision immunology approaches in inflammation and immunology with overlapping scientific leadership.

TypeBroad incumbent
Description

Markets Entyvio (vedolizumab, anti-α4β7), the direct competitor to SPY001 in ulcerative colitis and Crohn's. Entyvio's commercial performance is the primary benchmark for Spyre's α4β7 program.

TypeBroad incumbent
Description

Acquired Prometheus Biosciences for $10.8B to access its TL1A program. Now competing with Spyre's SPY002/SPY072 in TL1A for IBD and rheumatic indications with substantially larger commercial resources.

TypeBroad incumbent
Description

Develops immunology biologics including TL1A programs (acquired Telavant) and established IBD/rheumatic franchises. Competes with Spyre across multiple targeted mechanisms in overlapping indications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors20 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Spyre Therapeutics

Clinical-Stage Biopharmaceuticals (Immunology / IBD / Rheumatic Disease)spyre.com

Spyre Therapeutics is a clinical-stage biotechnology company developing YTE-modified monoclonal antibodies (SPY001, SPY002, SPY003, SPY072) and fixed-dose combinations for inflammatory bowel disease and rheumatic diseases, targeting quarterly or twice-annual dosing versus bi-weekly standards of care.

What Spyre Therapeutics does

Spyre Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel half-life extended monoclonal antibodies for inflammatory bowel disease (IBD) and rheumatic diseases. The company was rebranded in late 2023 from Aeglea BioTherapeutics and is publicly traded on NASDAQ under the ticker SYRE, headquartered in Waltham, Massachusetts, with 101–250 employees. Its core scientific platform applies the YTE modification to FcRn-binding regions of antibodies, producing a greater than 3x half-life extension that enables quarterly or twice-annual subcutaneous dosing compared with bi-weekly dosing for approved standards of care such as Takeda's Entyvio.

The pipeline comprises three monotherapy candidates (SPY001 targeting α4β7, SPY002 targeting TL1A, and SPY003 targeting IL-23) plus three fixed-dose combination products (SPY120, SPY130, SPY230) coformulated in single injectors, and a distinct anti-TL1A antibody (SPY072) for rheumatic indications. All candidates are investigational and being evaluated in Phase 2 studies including the SKYLINE-UC and SKYWAY-RD trials. Phase 2 data for SPY001 showed 40% clinical remission at Week 12 versus 27% for Entyvio, with 51% endoscopic improvement versus 41%, while SPY003 demonstrated approximately an 85-day confirmed half-life in interim Phase 1 results.

The business model is pre-revenue biopharmaceutical product sales contingent on regulatory approval; no products are approved or commercialized, and there are no published prices. The company has no commercial distribution infrastructure, but has appointed a Chief Commercial Officer (Kate Tansey Chevlen) in January 2026 to prepare for potential commercialization. As of year-end 2025, Spyre held approximately $757 million in cash, cash equivalents, and marketable securities, expected to fund operations into the second half of 2028, supported by capital raises totaling approximately $866.5 million across April 2026 offerings, $316.2 million in October 2025, and a $180 million private placement in March 2024.

Spyre Therapeutics firmographics

Firmographics
Name
Spyre Therapeutics
Legal name
Spyre Therapeutics, Inc.
Website
https://spyre.com
Company type
Public
Founded year
2023
Operating status
Operating
Headcount range
101–250 employees
Short description
Spyre Therapeutics is a clinical-stage biotechnology company developing YTE-modified monoclonal antibodies (SPY001, SPY002, SPY003, SPY072) and fixed-dose combinations for inflammatory bowel disease and rheumatic diseases, targeting quarterly or twice-annual dosing versus bi-weekly standards of care.
Ownership category
akta.pro rank

Spyre Therapeutics industry classification

Industry
Product category
Clinical-Stage Biopharmaceuticals (Immunology / IBD / Rheumatic Disease)
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Inflammatory bowel disease therapeutics
  • Monoclonal antibody development
  • Clinical-stage biotechnology
  • Immunology pipeline drugs
  • Rheumatic disease biologics

Where Spyre Therapeutics is headquartered

Location

Headquarters

HQ city
Waltham
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Spyre Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Biopharmaceutical Product Sales: Pre-revenue clinical-stage biotechnology company. The company is developing a pipeline of novel antibody therapeutics targeting inflammatory bowel disease and rheumatic diseases. Upon successful clinical development and regulatory approval, the company plans to commercialize its pipeline candidates. No products have been approved or commercialized yet.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Spyre Therapeutics product offering

Product offering

Core offering

Spyre Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel, half-life extended monoclonal antibodies targeting validated mechanisms (α4β7, TL1A, IL-23) for the treatment of inflammatory bowel disease (ulcerative colitis, Crohn's disease) and rheumatic diseases (rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis). The pipeline includes monotherapy candidates (SPY001, SPY002, SPY003, SPY072) and fixed-dose combination products (SPY120, SPY130, SPY230), all incorporating the YTE modification technology for extended half-life enabling quarterly or twice annual subcutaneous dosing.

Product overview

Spyre Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel half-life extended monoclonal antibodies targeting validated mechanisms for gastrointestinal and rheumatic diseases. The company's portfolio includes monotherapy candidates (SPY001 targeting α4β7, SPY002 targeting TL1A, SPY003 targeting IL-23) and combination products (SPY120, SPY130, SPY230) that pair these antibodies for enhanced efficacy. All antibodies incorporate the YTE modification for extended half-life enabling quarterly or twice annual dosing. The company is also developing SPY072, a distinct anti-TL1A antibody for rheumatic diseases.

Differentiator

Problem solved

Functional benefit

Products and services

  • SPY001 Novel, half-life extended monoclonal antibody targeting α4β7 for the potential treatment of inflammatory bowel disease (IBD), with demonstrated similar potency and selectivity as vedolizumab in preclinical studies and a differentiated pharmacokinetic profile supporting quarterly or twice annual maintenance dosing. Currently in Phase 2 clinical development (SKYLINE-UC).
  • SPY002 Novel, half-life extended monoclonal antibody targeting TL1A for the potential treatment of inflammatory bowel disease, exhibiting comparable or superior potency to first-generation anti-TL1As in head-to-head preclinical studies. Currently in Phase 2 clinical development (SKYLINE-UC trial; achieved 33% clinical remission and 42% endoscopic improvement at Week 12).
  • SPY003 Novel, half-life extended monoclonal antibody targeting IL-23 for the potential treatment of inflammatory bowel disease, exhibiting comparable potency to risankizumab in head-to-head preclinical studies and an approximately 85-day confirmed half-life in interim Phase 1 results. Currently in Phase 2 clinical development.
  • SPY120 High-concentration fixed-dose combination of SPY001 (anti-α4β7) and SPY002 (anti-TL1A) for the potential treatment of IBD, with superior efficacy compared to either monotherapy alone in preclinical colitis models, coformulated for delivery in a single injector on a quarterly or twice annual basis.
  • SPY130 High-concentration fixed-dose combination of SPY001 (anti-α4β7) and SPY003 (anti-IL-23) for the potential treatment of IBD, demonstrating additive efficacy in preclinical colitis models, coformulated for single-injector delivery on a quarterly or twice annual basis.
  • SPY230 High-concentration fixed-dose combination of SPY002 (anti-TL1A) and SPY003 (anti-IL-23) for the potential treatment of IBD, demonstrating additive efficacy in preclinical models, coformulated for single-injector delivery on a quarterly or twice annual basis.
  • SPY072 Novel, half-life extended monoclonal antibody targeting TL1A for the potential treatment of rheumatic diseases including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). Distinct from SPY002 which is being studied in IBD. Currently in Phase 2 clinical development (SKYWAY-RD).

Quantifiable outcome

  • SPY001 achieved 40% clinical remission rate at Week 12 vs 27% for Entyvio in ulcerative colitis
  • +4 more outcomes

Companies that use Spyre Therapeutics

Customer profile

Segments3 records

Ideal customer profiles1 record

Spyre Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Spyre Therapeutics partnerships and signals

Strategic signal

Scale indicators14 records

Recent moves6 records

Expansion highlights6 records

Spyre Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • AbbVie: Markets Skyrizi (risankizumab, anti-IL-23) and Humira in IBD/rheumatic diseases. Directly competes with SPY003 in IL-23 mechanism and sets the efficacy bar Spyre's programs must clear.
  • Johnson & Johnson: Markets Tremfya (anti-IL-23) and Stelara in IBD and rheumatic indications. Major incumbent across Spyre's two therapeutic areas with established commercial infrastructure.
  • Eli Lilly: Markets mirikizumab (Omvoh) in ulcerative colitis and acquired Morphic for its integrin pipeline. Direct competitor in IBD and a likely strategic acquirer of immunology-focused biotechs.
  • Takeda Pharmaceutical: Markets Entyvio (vedolizumab, anti-α4β7), the direct competitor to SPY001 in ulcerative colitis and Crohn's. Entyvio's commercial performance is the primary benchmark for Spyre's α4β7 program.
  • Merck & Co. Acquired Prometheus Biosciences for $10.8B to access its TL1A program. Now competing with Spyre's SPY002/SPY072 in TL1A for IBD and rheumatic indications with substantially larger commercial resources.
  • Roche: Develops immunology biologics including TL1A programs (acquired Telavant) and established IBD/rheumatic franchises. Competes with Spyre across multiple targeted mechanisms in overlapping indications.

Direct peers

  • Apogee Therapeutics: Clinical-stage immunology biotech developing antibody therapies for inflammatory diseases, with overlapping TL1A and IL-23 programs in IBD. Board member Michael Henderson is CEO of Apogee, creating direct portfolio overlap with Spyre.
  • Prometheus Biosciences: Was a clinical-stage IBD-focused biotech developing TL1A antibody therapy (PRA023) before being acquired by Merck for $10.8B. Directly comparable pipeline focus and the source of multiple Spyre team members.
  • Morphic Holding: Clinical-stage biotech developing oral integrin therapies for IBD, acquired by Eli Lilly for ~$3.2B. Directly comparable as an IBD-focused immunology platform targeting validated mechanisms with differentiated delivery.

Emerging players

  • Mirador Therapeutics: Recently formed immunology biotech led by Mark McKenna (Spyre board member). Pursues precision immunology approaches in inflammation and immunology with overlapping scientific leadership.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Spyre Therapeutics social profiles

Digital presence

Spyre Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Spyre Therapeutics leadership team

Management profile

Number of profiles

Profiles13 records

Spyre Therapeutics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors20 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Spyre Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Spyre Therapeutics

What does Spyre Therapeutics do?

Spyre Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel, half-life extended monoclonal antibodies targeting validated mechanisms (α4β7, TL1A, IL-23) for the treatment of inflammatory bowel disease (ulcerative colitis, Crohn's disease) and rheumatic diseases (rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis). The pipeline includes monotherapy candidates (SPY001, SPY002, SPY003, SPY072) and fixed-dose combination products (SPY120, SPY130, SPY230), all incorporating the YTE modification technology for extended half-life enabling quarterly or twice annual subcutaneous dosing.

Is Spyre Therapeutics a public or private company?

Spyre Therapeutics is a public company. It is classified as public and is currently operating.

When was Spyre Therapeutics founded?

Spyre Therapeutics was founded in 2023. It employs 101 to 250 people.

Where is Spyre Therapeutics based?

Spyre Therapeutics is headquartered in Waltham, United States, in the North America region.

How does Spyre Therapeutics make money?

One revenue line is on record: biopharmaceutical Product Sales.

Who are Spyre Therapeutics's main competitors?

Broad incumbents on record are AbbVie, Johnson & Johnson, Eli Lilly, Takeda Pharmaceutical, Merck & Co. and Roche. Direct peers are Apogee Therapeutics, Prometheus Biosciences and Morphic Holding. Mirador Therapeutics is listed as an emerging player.

Does Spyre Therapeutics have an API?

No public API is recorded for Spyre Therapeutics.

What industry is Spyre Therapeutics in?

Spyre Therapeutics's product category is Clinical-Stage Biopharmaceuticals (Immunology / IBD / Rheumatic Disease). Its primary akta.pro industry code is HLAIACAE, Gastroenterology Specialty Pharmaceuticals, with a secondary code of HLAAAAAF, Bispecific & Multispecific Antibodies. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaSpyre Therapeutics, Inc. (SYRE) Presents at UBS Global Biopharma Conference 2026 TranscriptSpyre Therapeutics CEO Cameron Turtle presented at the UBS Global Biopharma Conference, outlining the company's strategy to engineer antibodies for serious autoimmune diseases. He noted that many approved therapies hit a therapeutic ceiling, such as a 25% placebo-adjusted remission rate in IBD, and expressed hope to exceed that for a disease affecting over 2 million U.S. patients.Simply Wall StShould Wider Losses Require Action From Spyre Therapeutics (SYRE) Investors?Spyre Therapeutics reported a Q3 2026 net loss of $96.12 million and a nine-month loss of $201.33 million, with basic loss per share of $0.94 and $2.04 respectively. The company holds about $1.1 billion in cash, providing runway into 2029, while Phase 2 trials for SKYLINE and SKYWAY are guided for Q4 2026.Investing.comSpyre Therapeutics stock hits 52-week high at 110.28 USDSpyre Therapeutics stock reached a 52-week high of 110.28 USD, trading 1% below its peak. The stock has surged 217% year-to-date, with a 1-year total return of 361% and market cap of 10.44 billion USD. Analysts from UBS, JPMorgan, and others have initiated or reiterated Buy/Overweight ratings, citing IBD and rheumatoid arthritis pipeline potential.American Banking and Market NewsSpyre Therapeutics, Inc. (NASDAQ:SYRE) Stock Has Consensus Price Target of $110.40Spyre Therapeutics shares received a Moderate Buy consensus from 17 brokerages, with an average 1-year price target of $110.53. The company reported Q3 EPS of -$0.94, missing the -$0.82 consensus, and insiders sold 138,064 shares over three months. Analysts forecast a current-year EPS of -$2.78.Business & FinancialSpyre Therapeutics Announces Grants Of Inducement AwardsSpyre Therapeutics granted stock options and restricted stock units to employees, with options priced at $95.51 per share. Options vest one-fourth on the first anniversary and monthly thereafter, while RSUs vest one-fourth each November 15. Both are subject to the 2018 plan.TradingViewWedbush maintains Spyre Therapeutics at Outperform, lowers price target to $120 from $123Wedbush maintained Spyre Therapeutics at Outperform and lowered its price target to $120 from $123, a 2.4% decrease. The price target implies an upside of 20.9% from the Nov 3 close of $99.27.American Banking and Market NewsReviewing Spyre Therapeutics (NASDAQ:SYRE) & Regeneron Pharmaceuticals (NASDAQ:REGN)Spyre Therapeutics and Regeneron Pharmaceuticals are compared on valuation, earnings, and analyst ratings. Spyre has a stronger consensus rating and higher upside, but Regeneron has higher revenue and earnings. Spyre is more volatile and less profitable.TradingViewSpyre Therapeutics Reports Q3 2026 Net Loss of $96.1 Million, Advances IBD and HS ProgramsSpyre Therapeutics reported a Q3 2026 net loss of $96.1 million, up from $11.2 million a year earlier, with R&D expenses of $89.2 million. The company held $1.07 billion in cash as of September 30 and reported positive induction data for SPY003 in its Phase 2 SKYLINE trial.YahooSpyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateSpyre Therapeutics reported Q3 2026 financial results and program updates, including positive topline induction data for SPY003 in the SKYLINE IBD trial and positive RA sub-study data for SPY072. The company raised over $400 million in an October offering, leaving $1.5 billion in pro forma cash with runway into 2029. SPY072 will not be advanced in rheumatic diseases.Business & FinancialSpyre Therapeutics Reports Third Quarter 2026 Financial Results And Provides Corporate UpdateSpyre Therapeutics reported Q3 2026 financial results and program updates, including positive topline induction data for SPY003 in the SKYLINE IBD trial and positive RA sub-study data for SPY072. The company raised over $400 million in an October 2026 offering, leaving $1.5 billion in pro forma cash with runway into 2029. It plans to deliver SKYLINE combination topline data in Q3 2027.